GoAI
Get started
MediNet Group Limited logo

MediNet Group Limited

8161.HK

HKSEHealthcareMedical - Care Facilities

Open in GoAI

Latest quote

HK$0.47

−HK$0.025 · -5.05%

Aug 19, 10:13 AM HKTData delayed

8161.HK company overview

Historical prices · Market data may be delayed.

Company profile

Company website

MediNet Group Limited, an investment holding entity, delivers a wide array of medical and dental services to corporations, insurance companies, and private individuals across Hong Kong and the People's Republic of China. The company manages two MediNet Centres, providing general practitioner consultations, immunization programs, men's health services, and comprehensive health assessments and body check-ups. Its operations also encompass six dental clinics, which offer a full spectrum of oral care, from routine services like scaling, polishing, fillings, and intra-oral X-rays, to advanced treatments such as cosmetic dentistry, orthodontics (including Invisalign), restorative solutions (dentures, veneers, implants), and oral and dental laser implant surgery, catering to both plan members and self-paying clients. Furthermore, MediNet operates a dedicated DNA genetic laboratory. The group also extends its services to include physiotherapy, traditional Chinese medicine practitioners, vaccinations, X-ray and diagnostic laboratory tests, and various specialist medical consultations. Additionally, MediNet utilizes online platforms to facilitate the sale of dental and medical consultation services. Established in 1994, the company is headquartered in Causeway Bay, Hong Kong, and operates as a subsidiary of MediNet International Limited.

Industry
Medical - Care Facilities
Sector
Healthcare
Headquarters
HK
CEO
Chi Wai Chan
Listed since
May 31, 2016
Employees
80

Market position

Day range

Current HK$0.47

52-week range

Current HK$0.47

Open
HK$0.495
Previous close
HK$0.495
Volume
16K
4.6× average
Average volume
3.48K
Average daily volume
Market cap
19.55M HKD
Beta
0.48
Market reference 1
50-day average
HK$0.6442
-27.04% below average
200-day average
HK$0.5868
-19.90% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
23.81M HKD
P/E (TTM)
-6.03×
P/B (TTM)
2.34×
P/S (TTM)
0.23×
EV / EBITDA
5.82×
Earnings yield
-14.43%
Free cash flow yield
4.86%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
11.30%
Operating margin
-4.62%
Net margin
-3.89%
Return on equity
-38.72%
Return on assets
-8.81%
Return on invested capital
-19.66%

Financial health

Debt / equity
1.38×
Current ratio
0.82×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends62%31%0%-30%Gross margin, FY2021: 54.05%Gross margin, FY2022: 51.35%Gross margin, FY2023: 13.07%Gross margin, FY2024: 51.85%Gross margin, FY2025: 9.03%Operating margin, FY2021: -6.15%Operating margin, FY2022: -9.85%Operating margin, FY2023: -4.40%Operating margin, FY2024: 8.29%Operating margin, FY2025: -4.62%Net margin, FY2021: -5.13%Net margin, FY2022: -22.54%Net margin, FY2023: -6.95%Net margin, FY2024: 7.58%Net margin, FY2025: -3.89%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 54.05%. Gross margin FY2022 51.35%. Gross margin FY2023 13.07%. Gross margin FY2024 51.85%. Gross margin FY2025 9.03%. Operating margin FY2021 -6.15%. Operating margin FY2022 -9.85%. Operating margin FY2023 -4.40%. Operating margin FY2024 8.29%. Operating margin FY2025 -4.62%. Net margin FY2021 -5.13%. Net margin FY2022 -22.54%. Net margin FY2023 -6.95%. Net margin FY2024 7.58%. Net margin FY2025 -3.89%.

Income trends

Revenue

83.4M HKD-21.61%

Operating income

−3.86M HKD−12.68M HKD

Net income

−3.24M HKD−11.3M HKD
Income trends across reported periods135.66M HKD77.28M HKD18.9M HKD−39.48M HKDRevenue, FY2021: 121.07M HKDRevenue, FY2022: 110.39M HKDRevenue, FY2023: 116.25M HKDRevenue, FY2024: 106.39M HKDRevenue, FY2025: 83.4M HKDOperating income, FY2021: −7.45M HKDOperating income, FY2022: −10.88M HKDOperating income, FY2023: −5.12M HKDOperating income, FY2024: 8.82M HKDOperating income, FY2025: −3.86M HKDNet income, FY2021: −6.22M HKDNet income, FY2022: −24.88M HKDNet income, FY2023: −8.08M HKDNet income, FY2024: 8.06M HKDNet income, FY2025: −3.24M HKDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 121.07M HKD. Revenue FY2022 110.39M HKD. Revenue FY2023 116.25M HKD. Revenue FY2024 106.39M HKD. Revenue FY2025 83.4M HKD. Operating income FY2021 −7.45M HKD. Operating income FY2022 −10.88M HKD. Operating income FY2023 −5.12M HKD. Operating income FY2024 8.82M HKD. Operating income FY2025 −3.86M HKD. Net income FY2021 −6.22M HKD. Net income FY2022 −24.88M HKD. Net income FY2023 −8.08M HKD. Net income FY2024 8.06M HKD. Net income FY2025 −3.24M HKD.
Metric (HKD)FY2025FY2024FY2023FY2022FY2021
Revenue83.4M HKD106.39M HKD116.25M HKD110.39M HKD121.07M HKD
Cost of goods sold75.86M HKD51.23M HKD101.05M HKD53.71M HKD55.63M HKD
Gross profit7.53M HKD55.16M HKD15.2M HKD56.68M HKD65.44M HKD
Selling, general, and administrative11.39M HKD19.87M HKD20.5M HKD1.87M HKD1.14M HKD
Operating expenses11.39M HKD46.34M HKD20.31M HKD50.8M HKD57.84M HKD
Interest income—106K HKD163K HKD8K HKD3K HKD
Interest expense482K HKD655K HKD660K HKD560K HKD650K HKD
Depreciation and amortization7.95M HKD8.79M HKD9.73M HKD13.31M HKD14.15M HKD
Operating income−3.86M HKD8.82M HKD−5.12M HKD−10.88M HKD−7.45M HKD
Net income−3.24M HKD8.06M HKD−8.08M HKD−24.88M HKD−6.22M HKD

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
-0

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates0.260.130.01-0.11Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q1 '25Q3 '25
Q4 2023, reported Nov 14, 2023: actual -0.031, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Feb 10, 2024: actual -0.07, estimate —, surprise —, Comparison unavailable. Q2 2024, reported Jun 26, 2024: actual -0.07, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 9, 2024: actual -0.011, estimate —, surprise —, Comparison unavailable. Q4 2024, reported Nov 25, 2024: actual -0.011, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Feb 10, 2025: actual 0.108, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 31, 2025: actual 0.216, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Sep 30, 2025: actual -0.001, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly Revenue actual values compared with estimates50.46M41.08M31.7M22.32MQ4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q1 '25Q3 '25
Q4 2023, reported Nov 14, 2023: actual 28.96M HKD, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Feb 10, 2024: actual 29.08M HKD, estimate —, surprise —, Comparison unavailable. Q2 2024, reported Jun 26, 2024: actual 29.08M HKD, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 9, 2024: actual 28.94M HKD, estimate —, surprise —, Comparison unavailable. Q4 2024, reported Nov 25, 2024: actual 28.94M HKD, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Feb 10, 2025: actual 24.26M HKD, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 31, 2025: actual 48.52M HKD, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Sep 30, 2025: actual 43.38M HKD, estimate —, surprise —, Comparison unavailable.

Corporate actions

Corporate action history

Stock split

Effective Aug 15, 2022

1:25

8161.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.8

-3.89%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.74

-3.03%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$222.4

-2.46%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.60

-4.71%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.22

-5.62%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$100.2

-2.15%

Continue in GoAI

Research 8161.HK

research.disclaimer